IQVIA Holdings Inc. (IQV) News
Filter IQV News Items
IQV News Results
|Loading, please wait...|
IQV News Highlights
- IQV's 30 day story count now stands at 61.
- Over the past 21 days, the trend for IQV's stories per day has been choppy and unclear. It has oscillated between 1 and 20.
- The most mentioned tickers in articles about IQV are PRA, AB and NOV.
Latest IQV News From Around the Web
Below are the latest news stories about Iqvia Holdings Inc that investors may wish to consider to help them evaluate IQV as an investment opportunity.
RESEARCH TRIANGLE PARK, N.C., February 24, 2022--IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry was named the top CRO in Overall Reputation by clinical trial sites around the world in the 2021 WCG CenterWatch Global Site Relationship Benchmark Survey Report.
Earnings season is coming to an end, with some corporations still to report this week and next. The earnings results so far this reporting cycle have generally been encouraging, and momentum should remain high over the remainder of the reporting period. Despite better-than-expected earnings results, investors have become increasingly anxious as a result of market uncertainty over inflation, political disturbances, rate rises, supply-chain challenges, labor issues, and other factors. In such a market, TipRanks' Smart Score System, which allows investors to do a more thorough analysis of a firm before investing in it, may be beneficial.
RESEARCH TRIANGLE PARK, N.C., February 22, 2022--IQVIA (NYSE:IQV) today published its 2021 Environmental, Social, and Governance (ESG) Report. The annual report highlights the significant efforts the company has made in advancing healthcare globally, increasing the diversity and engagement of its workforce, and reducing its global environmental footprint.
In a report released yesterday, David Windley from Jefferies maintained a Buy rating on IQVIA Holdings (IQV – Research Report), with a price target of $293.00. The company's shares closed last Wednesday at $232.18. According to TipRanks.com, Windley is a top 100 analyst with an average return of 17.1% and a 70.8% success rate. Windley covers the Healthcare sector, focusing on stocks such as UnitedHealth, Catalent, and Humana. The word on The Street in general, suggests a Strong Buy analyst consensus rating for IQVIA Holdings with a $293.09 average price target, representing a 28.3% upside.
IQVIA Holdings with ticker code (IQV) have now 17 analysts in total covering the stock. The consensus rating is ''Buy''. The range between the high target price and low target price is between 325 and 255 with the average target price sitting at 289.94. Given that the stocks previous close was at 228.64 this is indicating there is a potential upside of 26.8%. The day 50 moving average is 257.76 and the 200 moving average now moves to 251.16. The company has a market capitalisation of $44,356m. Company Website: https://www.iqvia.com [stock_market_widget type="chart" symbol="IQV" chart="bar" range="6mo" interval="1d" line-color="rgb(49, 125, 189)"] The potential market cap would be $56,248m based on the market concensus. IQVIA Holdings Inc. provides advanced analytics, technology solution...
Today's Research Daily features new research reports on 16 major stocks, including Adobe Inc. (ADBE), Altria Group, Inc. (MO), and Marriott International, Inc. (MAR).
After Robert W. Baird and Stifel Nicolaus gave IQVIA Holdings (NYSE: IQV) a Buy rating last month, the company received another Buy, this time from Morgan Stanley. Analyst Tejas Savant maintained a Buy rating on IQVIA Holdings today and set a price target of $280.00. The company's shares closed last Wednesday at $226.32. According to TipRanks.com, Savant is a 1-star analyst with an average return of -5.1% and a 35.4% success rate. Savant covers the Healthcare sector, focusing on stocks such as Nautilus Biotechnolgy, Akoya Biosciences, and Cytek Biosciences. IQVIA Holdings has an analyst consensus of Strong Buy, with a price target consensus of $302.08, implying a 32.
IQVIA Holdings, Inc. (NYSE: IQV) Q4 2021 earnings call dated Feb. 15, 2022 Presentation: Operator Ladies and gentlemen, thank you for standing by. At this time, I would like to… […] The post IQVIA Holdings, Inc. (IQV) Q4 2021 Earnings Call Transcript first appeared on AlphaStreet .
No summary available.
No summary available.